Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
REGULATORY
Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
Kowa took a pass on the reimbursement listing in August of its hoped-to-be big-seller hyperlipidemia drug Parmodia (pemafibrate) as it failed to reach an agreement with regulators on its pricing, a spokesperson said on August 23. This means its launch…
To read the full story
Related Article
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
November 20, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Kowa President Has High Hopes for Livalo Successor Parmodia
July 20, 2017
REGULATORY
- Japan PM Warns of Overreliance on China for Pharmaceutical Ingredients
October 29, 2025
- Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Takaichi Vows Cross-Party Talks on Social Security Reform
October 27, 2025
- Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
October 27, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…